SEC Tracker
Get the app

AngioDynamics ANGO

AngioDynamics FY 2022: revenue $316.2M, up 9%; diluted EPS −$0.68

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers AngioDynamics reported for the year ended May 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$316.2M+9% from $291.0M in FY 202110-K income statement, on EDGAR
  2. Net income−$26.5MAgainst −$31.5M in FY 202110-K income statement, on EDGAR
  3. Diluted EPS−$0.68Against −$0.82 in FY 202110-K income statement, on EDGAR
  4. Cash and cash equivalents$28.8M−40% from $48.2M in FY 202110-K balance sheet, on EDGAR
  5. Cash from operations−$7.2M−130% from $24.1M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when AngioDynamics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Orthofix Medical OFIX public float $440M, Jun 30, 2025
  2. Axogen AXGN public float $431M, Jun 30, 2025
  3. Delcath Systems DCTH public float $420M, Jun 30, 2025
  4. Ceribell CBLL public float $417M, Jun 30, 2025
  5. Iradimed IRMD public float $481M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.